Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan (Q37104853)

18 August 2017

1 reference

title

Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan (English)

1 reference

18 August 2017

arterial hypertension

0 references

author name string

Emilio A Francischetti

1

1 reference

18 August 2017

Bruno M J Celoria

2

1 reference

18 August 2017

Aloisio Francischetti

3

1 reference

18 August 2017

Virginia A Genelhu

4

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Cardiovascular Therapy

18 August 2017

1 reference

18 August 2017

6

1 reference

18 August 2017

3

1 reference

18 August 2017

289-303

1 reference

Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Global burden of hypertension: analysis of worldwide data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes As

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Metabolic safety of antihypertensive drugs: myth versus reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Abdominal obesity and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The metabolic syndrome in hypertension: diagnostic and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Receptor-mediated regional sympathetic nerve activation by leptin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Selective resistance to central neural administration of leptin in agouti obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Interactions between leptin and the human sympathetic nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Plasma angiotensinogen concentrations in obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Fat cell metabolism: insulin, fatty acids, and renin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Mechanisms of hypertension and kidney disease in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Human adipocytes secrete mineralocorticoid-releasing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The kidney, hypertension, and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Blood pressure, insulin, and glycemia in nondiabetic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Endothelial dysfunction in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Hypoadiponectinemia is associated with blood pressure increase in obese insulin-resistant individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Glucose intolerance in hypertensive patients treated with diuretics; a fourteen-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Drug-induced hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

A systematic review of drug therapy to delay or prevent type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

New-onset diabetes and antihypertensive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

21 January 2018

Essential hypertension

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Risks and benefits in the trial of the European Working Party on High Blood Pressure in the Elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Bakhsheesh culture contributes to Turkey's misery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Ramipril and the development of diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Adverse prognostic significance of new diabetes in treated hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Predictive Properties of Impaired Glucose Tolerance for Cardiovascular Risk Are Not Explained by the Development of Overt Diabetes During Follow-Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Telmisartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.289

21 January 2018

Identifiers

DOI

10.1586/14779072.6.3.289

1 reference

18 August 2017

1 reference